Last reviewed · How we verify

MCM Vaccines B.V. — Portfolio Competitive Intelligence Brief

MCM Vaccines B.V. pipeline: 1 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 4 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Pediacel® Pediacel® marketed Combination vaccine Immunology / Infectious Disease Prevention
MCC-CRM MCC-CRM phase 3 Conjugate vaccine Neisseria meningitidis serogroup C polysaccharide capsule Immunology / Infectious Disease
MCC-TT MCC-TT phase 3 Conjugate vaccine Immunology / Infectious Disease
Hib-MCC Hib-MCC phase 3 Conjugate vaccine Immunology / Infectious Disease
PR5I PR5I phase 3 Therapeutic vaccine Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Merck Sharp & Dohme LLC · 3 shared drug classes
  2. GlaxoSmithKline · 3 shared drug classes
  3. Serum Institute of India Pvt. Ltd. · 2 shared drug classes
  4. Jiangsu Province Centers for Disease Control and Prevention · 2 shared drug classes
  5. Sanofi · 2 shared drug classes
  6. Sanofi Pasteur, a Sanofi Company · 2 shared drug classes
  7. PT Bio Farma · 2 shared drug classes
  8. CHU de Quebec-Universite Laval · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MCM Vaccines B.V.:

Cite this brief

Drug Landscape (2026). MCM Vaccines B.V. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mcm-vaccines-b-v. Accessed 2026-05-16.

Related